May 27, 2023
Listen to Ark Invest’s Podcast: Bettering Human Health Through Artificial Intelligence with Sean McClain and Joshua Meier of Absci Drug development is an extremely expensive endeavor, in large part because of the 96% failure rate of clinical drug trials....
May 13, 2023
Monoclonal antibodies (y-shaped) binding to sites on a SARS-CoV-2 virus spike protein (red) (artist’s conception).Credit: Juan Gaertner/Science Photo Library At the height of the pandemic, researchers raced to develop some of the first effective treatments against...
May 13, 2023
The partnership will use Absci’s integrated drug creation platform and the Kennedy Institute’s clinical immunology datasets. Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven...
May 13, 2023
Joshua Meier, Absci Senior VP and Chief AI Officer Absci says it is on track to advance its first antibody developed through its generative artificial intelligence (AI)-based platform to IND stage within the next 24 months, after the company disclosed expanded data...
Apr 4, 2023
04/04/2023 Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments faster VANCOUVER, Wash. and TAMPA, Fla., April 04, 2023 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a...
